Search Results - "DRUKER, B. J"

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia by Hochhaus, A, O'Brien, S G, Guilhot, F, Druker, B J, Branford, S, Foroni, L, Goldman, J M, Müller, M C, Radich, J P, Rudoltz, M, Mone, M, Gathmann, I, Hughes, T P, Larson, R A

“…Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized,…”
Get full text

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors by Traer, E, MacKenzie, R, Snead, J, Agarwal, A, Eiring, A M, O'Hare, T, Druker, B J, Deininger, M W

Get full text

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy by HOCHHAUS, A, KREIL, S, GSCHAIDMEIER, H, DRUKER, B. J, HEHLMANN, R, CORBIN, A. S, ROSEE, P. La, MÜLLER, M. C, LAHAYE, T, HANFSTEIN, B, SCHOCH, C, CROSS, N. C. P, BERGER, U

“…Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (STI571, Glivec/Gleevec) is a promising new therapeutic strategy in patients with chronic…”
Get full text

Age-related mutations and chronic myelomonocytic leukemia by Mason, C C, Khorashad, J S, Tantravahi, S K, Kelley, T W, Zabriskie, M S, Yan, D, Pomicter, A D, Reynolds, K R, Eiring, A M, Kronenberg, Z, Sherman, R L, Tyner, J W, Dalley, B K, Dao, K-H, Yandell, M, Druker, B J, Gotlib, J, O'Hare, T, Deininger, M W

“…Chronic myelomonocytic leukemia (CMML) is a hematologic malignancy nearly confined to the elderly. Previous studies to determine incidence and prognostic…”
Get full text

Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia by Watanabe-Smith, K, Tognon, C, Tyner, J W, Meijerink, J P P, Druker, B J, Agarwal, A

Get full text

Targeting survivin and p53 in pediatric acute lymphoblastic leukemia by Tyner, J W, Jemal, A M, Thayer, M, Druker, B J, Chang, B H

“…Despite advances in treatment and outcomes for patients with pediatric acute lymphoblastic leukemia (ALL), there continue to be subsets of patients who are…”
Get full text

Recurrent cyclin D2 mutations in myeloid neoplasms by Khanna, V, Eide, C A, Tognon, C E, Maxson, J E, Wilmot, B, Bottomly, D, McWeeney, S, Edwards V, D K, Druker, B J, Tyner, J W

Get full text

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib by SHERBENOU, D. W, WONG, M. J, DEININGER, M. W, HUMAYUN, A, MCGREEVEY, L. S, HARRELL, P, YANG, R, MAURO, M, HEINRICH, M. C, PRESS, R. D, DRUKER, B. J

“…Residual leukemia is demonstrable by reverse transcriptase-polymerase chain reaction in most patients with chronic myeloid leukemia who obtain a complete…”
Get full text

Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells by CHUAH, C, BARNES, D. J, KWOK, M, CORBIN, A, DEININGER, M. W. N, DRUKER, B. J, MELO, J. V

“…Although imatinib mesylate has revolutionized the treatment of chronic myeloid leukaemia (CML), resistance to the drug, manifesting as relapse after an initial…”
Get full text

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia by Sherbenou, D W, Hantschel, O, Turaga, L, Kaupe, I, Willis, S, Bumm, T, Press, R D, Superti-Furga, G, Druker, B J, Deininger, M W

“…The BCR-ABL oncogenic tyrosine kinase causes chronic myeloid leukemia and is the target for imatinib therapy. During imatinib treatment, cells are selected in…”
Get full text

Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography by DEININGER, M. W. N, MCGREEVEY, L, WILLIS, S, BAINBRIDGE, T. M, DRUKER, B. J, HEINRICH, M. C

“…Mutations of the ABL kinase domain (KD) are common in patients with chronic myelogenous leukemia (CML) who develop resistance to imatinib. We developed an…”
Get full text

An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia by Agarwal, A, Eide, C A, Harlow, A, Corbin, A S, Mauro, M J, Druker, B J, Corless, C L, Heinrich, M C, Deininger, M W

Get full text

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative by BUCHDUNGER, E, ZIMMERMANN, J, METT, H, MEYER, T, MÜLLER, M, DRUKER, B. J, LYDON, N. B

“…Oncogenic activation of Abl proteins due to structural modifications can occur as a result of viral transduction or chromosomal translocation. The tyrosine…”
Get full text

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective by La Rosée, P, O'Dwyer, M E, Druker, B J

“…Clinical phase I/II studies with the Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec, formerly STI571) for the treatment for chronic myelogenous…”
Get full text

Thrombopoietin Induces Tyrosine Phosphorylation of Stat3 and Stat5 in Human Blood Platelets by Miyakawa, Yoshitaka, Oda, Atsushi, Druker, Brian J., Miyazaki, Hiroshi, Handa, Makoto, Ohashi, Hideya, Ikeda, Yasuo

“…Thrombopoietin is known to be essential for megakaryocy-topoiesis and thrombopoiesis. Recently, we and others have shown that thrombopoietin induces rapid…”
Get full text

Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells by MacPartlin, M, Smith, A M, Druker, B J, Honigberg, L A, Deininger, M W

“…Bcr-Abl, a constitutively active tyrosine kinase, is the cause of chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemias (ALL). Bruton's…”
Get full text

Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate by O'Dwyer, M E, Gatter, K M, Loriaux, M, Druker, B J, Olson, S B, Magenis, R E, Lawce, H, Mauro, M J, Maziarz, R T, Braziel, R M

“…Imatinib mesylate, an Abl-specific kinase inhibitor, produces sustained complete hematologic responses (CHR) and major cytogenetic responses (MCR) in chronic…”
Get full text

Recombinant Thrombopoietin Induces Rapid Protein Tyrosine Phosphorylation of Janus Kinase 2 and Shc in Human Blood Platelets by Miyakawa, Yoshitaka, Oda, Atsushi, Druker, Brian J., Kato, Takashi, Miyazaki, Hiroshi, Handa, Makoto, Ikeda, Yasuo

“…A cDNA for the thrombopoietin has been cloned by several groups. The recombinant thrombopoietin has been reported to stimulate the megakaryocytopoiesis and…”
Get full text

A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib by CROSSMAN, L. C, O'HARE, T, DEININGER, M. W. N, LANGE, T, WILLIS, S. G, STOFFREGEN, E. P, CORBIN, A. S, O'BRIEN, S. G, HEINRICH, M. C, DRUKER, B. J, MIDDLETON, P. G

“…We have identified a gene polymorphism (K247R) within or close to the P-loop of BCR-ABL, which leads to the substitution of arginine for lysine. We…”
Get full text

Thrombopoietin Primes Human Platelet Aggregation Induced by Shear Stress and by Multiple Agonists by Oda, Atsushi, Miyakawa, Yoshitaka, Druker, Brian J., Ozaki, Katsutoshi, Yabusaki, Katsumi, Shirasawa, Yoshiaki, Handa, Makoto, Kato, Takashi, Miyazaki, Hiroshi, Shimosaka, Akihiro, Ikeda, Yasuo

“…Recombinant thrombopoietin has been reported to stimulate megakaryocytopoiesis and thrombopoiesis and it may be quite useful to treat patients with low…”
Get full text